COLO B Coloplast A/S Class B

Coloplast A/S - Decisions at the Annual General Meeting 2024

Coloplast A/S - Decisions at the Annual General Meeting 2024

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:

  • The annual report for the financial year 2023/24 was approved.
  • Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2023/24 to DKK 22.00 per share of nominally DKK 1.
  • The remuneration report for the financial year 2023/24 was approved.
  • The remuneration of the members of the Board of Directors for the financial year 2024/25 was approved.
  • Lars Søren Rasmussen, Niels Peter Louis-Hansen, Annette Brüls, Carsten Hellmann, Jette Nygaard-Andersen and Marianne Wiinholt were re-elected to the Board of Directors.
  • EY Godkendt Revisionspartnerselskab was re-elected as Coloplast A/S’ auditors. The election applies to statutory financial reporting as well as assurance engagements relating to sustainability reporting. 
  • Authorisation was granted to the chairman of the Annual General Meeting to make certain registrations with the Danish Business Authority and other authorities.

Immediately after the Annual General Meeting, the Board of Directors elected Lars Søren Rasmussen as Chairman and Niels Peter Louis-Hansen as Deputy Chairman. In addition to the members of the Board of Directors elected at the Annual General Meeting, the Board of Directors consists of three members elected by the employees: Thomas Barfod, Nikolaj Kyhe Gundersen and Roland Vendelbo Pedersen.

For further information, please contact

Investors and analysts

Anders Lonning-Skovgaard

Executive Vice President, CFO

Tel.

Aleksandra Dimovska

Vice President, Investor Relations

Tel. /

Email: 

Simone Dyrby Helvind

Senior Manager, Investor Relations

Tel. /

Email: 

Press and media

Peter Mønster

Sr. Media Relations Manager

Tel.

Email: 

Address

Coloplast A/S

Holtedam 1

DK-3050 Humlebaek

Denmark

Company reg. (CVR) no. 69749917

Website

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2024-12.

All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment



EN
05/12/2024

Underlying

COLO BColoplast A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Hold, TP: DKK770.00) - Expecting another weak quarter

We expect another soft quarter (7.8% organic revenue growth YOY and a 27.5% EBIT margin), before then improving. We look for unchanged 2024/25 guidance of 8–9% organic sales growth and a c28% EBIT margin before special items. We have cut our 2024/25–2026/27e EPS by 2.8% on average and believe returning to a 30%+ EBIT margin hinges on external factors. We reiterate our HOLD, but have cut our target price to DKK770 (850).

COLO B COLOPLAST A/S CLASS B
04/15/25 April 15, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference...

Coloplast A/S - H1 2024/25 Earnings Release - Invitation to conference call on 6 May 2025 at 11.00am CEST Tuesday, 6 May 2025 at 11.00 - 12.00am CESTIn connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the e...

April 15, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
COLO B Coloplast A/S C...

Coloplast (Hold, TP: DKK850.00) - 2024/25 likely back-end loaded

The Q1 headline results were broadly in line with our forecasts and consensus. We view 2024/25 as back-end loaded and expect a pick-up in organic growth and margins over the coming quarters. The company maintained its 2024/25 guidance for 8–9% organic sales growth and a c28% EBIT margin before special items. We reiterate our HOLD and DKK850 target price.

COLO B COLOPLAST A/S CLASS B
02/04/25 February 4, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
COLO B COLOPLAST A/S CLASS B
02/04/25 February 4, 2025 1 EN
 PRESS RELEASE
Free
COLO B Coloplast A/S C...

Coloplast A/S - Allocation of Share Options

Coloplast A/S - Allocation of Share Options Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy. The policy is available on the group website at this address:   Details of the person discharging managerial responsibi...

February 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch